Business Wire

Matchday Champions , a New Class of Mobile Football Game Now Available Worldwide; Kicks off With In-Game Event Hosted by Soccer Superstar Alexia Putellas and Mega Influencer Celine Dept

20.9.2024 14:00:00 EEST | Business Wire | Press release

Share

Matchday, the developer of innovative mobile games for football’s five billion fans, has debuted its newest title, Matchday Champions. Today, the game is in early access globally, and it is celebrating with the limited-time “Copa Alexia x Céline,” a one-of-a-kind in-game tournament hosted by Spanish football World Cup Champion Alexia Putellas, and the immensely popular Belgian influencer Celine Dept.

Backed by Lionel Messi’s Play Time fund, Alexia Putellas, and other industry legends in sports and games, Matchday Champions is a one-of-its-kind experience. The game allows players to collect, craft and manage their own dream squad made up of both men's and women's players. It delivers the excitement of football using a cutting edge narrative creation engine, ensuring no two matches are ever the same. More than two million people have already pre-registered ahead of launch. Matchday Champions is now available in early access globally for iOS and Android phones.

Players who download the game can sign up to participate in the Copa Alexia x Céline, beginning on September 20. Hosted by World Cup champion, two-time Ballon d’Or winner and UEFA Women's Player of the Year Alexia Putellas and influencer Celine Dept, a football mega-fan with more than 50 million followers on YouTube, TikTok and Instagram, Copa Alexia x Céline challenges players to join Team Alexia or Team Celine, squaring off in a virtual tournament for bragging rights and prizes.

“Matchday is elevating two things I am very passionate about: women’s football and inclusivity,” said Putellas. “Women’s football has been on the rise for the last decade and Matchday’s co-gender football squads represent this reality in a fun and novel way for fans. I am honored to be a part of and shape a (virtual) football world that gives men and women truly equal footing. I hope the sort of representation we see in Matchday’s games will inspire the women’s football stars and all football fans of tomorrow, and help to drive forward conversations around equality.”

Licensed by FIFA and FIFPRO, Matchday offers fans the ability to collect digital player cards from tens of thousands of soccer athletes, and to combine both men’s and women’s players into their ideal squad to go head-to-head with other players’ teams. Players begin by assembling their squad, which they can start upgrading immediately. They then send their starting 11 onto the pitch, and Matchday Champions' proprietary simulation engine renders exciting in-game narratives. Play against rivals and friends while earning resources and recruiting footballers to improve their squad. Matchday Champions authentically captures the euphoria and heartbreak of real life football, and every match unfolds in a unique way.

“Football is an emotional experience for its five billion fans worldwide, and now they will be able to experience the drama of the sport in a video game that can seamlessly simulate games based on real players, real stats, and more,” said Sebastien de Halleux, Matchday co-founder and chief gaming officer. “Few players have experienced the emotional highs of football like Alexia Putellas, winning a World Cup, three UEFA Women's Champion Leagues, and 21 domestic trophies, along with all of her incredible individual accolades, so we’re honored that she has joined us not only as a Matchday ambassador but as the host of our first global in-game tournament.”

In Matchday Champions, players build and strengthen their squad, competing against others to move up through divisions and grow their club, competing with friends and Matchday’s vibrant global community, already numbering in the millions. Custom squads can be set up with ease through Matchday Champions' intuitive and accessible interface, allowing players to experiment with their team formation, as well as buy, sell and share cards with friends. Players hone their team in single player mode, then step on the pitch for a friendly match or an epic league competition with fans from all over the world. They can also join fans on the official Discord in discussing everything football, participate in weekly contests, participate in AMAs with football celebrities and follow real-world football matches.

Matchday continues to push the boundaries of digital ownership with Matchday Champions, which is part of a new category of sports games wherein fans build virtual squads by collecting digital cards of their favorite footballers. Players have true ownership of their cards and other digital items within Matchday Champions as they collect, trade and grow their dream team. These officially licensed cards can be utilized in all games within the Matchday ecosystem as it continues to grow.

Matchday previously launched the trivia and match prediction game Matchday Challenge: FIFA Women’s World Cup AU∙NZ∙2023™ Edition, which ran during FIFA Women’s World Cup and was played by millions of players all over the world.

Players can download Matchday Champions for free on the App Store or Google Play.

To learn more, please visit matchday.com, and join Matchday on X and Discord for the latest updates.

About Matchday

Matchday builds games for 5 billion football fans featuring officially licensed players and tournaments, in partnership with FIFA and FIFPRO. The company was founded by technology and gaming veterans who have successfully started and sold companies including Playfish (acq. EA), Glu Mobile (IPO), Hoodline (acq. Nextdoor), Spin (acq. Ford), and Viki (acq. Rakuten). Matchday is incubated by Leo Messi’s Play Time and backed by leading investors, with teams in San Francisco and Barcelona.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240920697449/en/

Contacts

Sibel Sunar
fortyseven communications for Matchday
matchday@fortyseven.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye